OLD National Bancorp IN lowered its stake in Johnson & Johnson (NYSE:JNJ) by 0.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 167,562 shares of the company’s stock after selling 487 shares during the period. Johnson & Johnson makes up approximately 1.2% of OLD National Bancorp IN’s investment portfolio, making the stock its 17th biggest position. OLD National Bancorp IN’s holdings in Johnson & Johnson were worth $21,785,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Traynor Capital Management Inc. boosted its position in shares of Johnson & Johnson by 3.5% during the third quarter. Traynor Capital Management Inc. now owns 10,822 shares of the company’s stock valued at $1,401,000 after buying an additional 368 shares during the period. Crossmark Global Holdings Inc. purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $10,634,000. SPC Financial Inc. boosted its position in shares of Johnson & Johnson by 208.8% during the third quarter. SPC Financial Inc. now owns 11,611 shares of the company’s stock valued at $1,510,000 after buying an additional 7,851 shares during the period. Callahan Advisors LLC boosted its position in shares of Johnson & Johnson by 1.0% during the third quarter. Callahan Advisors LLC now owns 102,145 shares of the company’s stock valued at $13,280,000 after buying an additional 979 shares during the period. Finally, Independence Trust CO boosted its position in shares of Johnson & Johnson by 3.2% during the third quarter. Independence Trust CO now owns 30,217 shares of the company’s stock valued at $3,928,000 after buying an additional 931 shares during the period. Institutional investors own 65.70% of the company’s stock.
Several brokerages have issued reports on JNJ. Piper Jaffray Companies restated a “hold” rating and set a $120.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research report on Monday, September 18th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Wells Fargo & Co upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $140.00 to $149.00 in a research report on Monday, October 9th. Finally, JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $145.94.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.68 earnings per share. research analysts expect that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.31%. Johnson & Johnson’s payout ratio is 58.33%.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/13/old-national-bancorp-in-sells-487-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.